CRL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Charles River Laboratories International Inc (CRL) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock is currently oversold, but the technical indicators, weak financial performance, insider selling, and lack of recent positive news or catalysts suggest waiting for a clearer entry point. Analysts are generally optimistic, but the company's recent financials and market sentiment do not align with a strong buy recommendation at this time.
The MACD is negative and expanding (-6.366), indicating bearish momentum. RSI is at 10.653, suggesting the stock is heavily oversold. Moving averages are converging, showing no clear trend. The stock is trading near its key support level (S1: 158.513), but further downside risk remains.
Analysts have raised price targets recently, with several maintaining Buy ratings. The upcoming earnings report on February 18, 2026, could provide clarity on the company's outlook.
Insider selling has increased significantly (125.30% over the last month). The company's financial performance in Q3 2025 showed declines in revenue (-0.49% YoY), net income (-20.76% YoY), EPS (-17.29% YoY), and gross margin (-2.68% YoY). No recent news or significant hedge fund activity indicates a lack of positive momentum.
In Q3 2025, revenue decreased to $1.004 billion (-0.49% YoY), net income dropped to $54.42 million (-20.76% YoY), EPS fell to 1.1 (-17.29% YoY), and gross margin declined to 32.32% (-2.68% YoY). These metrics indicate weakening financial health.
Recent analyst ratings are generally positive, with multiple firms raising price targets (e.g., TD Cowen to $251, Citi to $265, Baird to $224). However, some analysts maintain Neutral ratings, citing concerns about healthcare utilization trends and market conditions.
